Continuous Glucose Monitor to Improve Diabetes Mellitus

Overview

About this study

The purpose of this study is to to prove that personal real time CGMs brought in the hospital at the time of hospitalization can be safely used to guide insulin therapy and to diminish the hypoglycemia and hyperglycemia episodes. CGM real time data will be transmited to diabetes treatment team for daily review.

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients with age above 18 years old at the time of informed consent.
  • Male or female.
  • Admitted to non-ICU setting in brick-and-mortar medical and surgical ward or admitted to Advanced Care at Home Program.
  • Admitted under observation or inpatient status.
  • Expected to remain in the hospital for more than 48 hours.
  • Patients that are using a transcutaneous or implantable real time CGM as outpatient and are bringing it in the hospital.
  • Patients with diagnosis of diabetes mellitus or hyperglycemia requiring treatment with SQ insulin in the hospital either with multiple daily injections or subcutaneous infusion of insulin via insulin pump.

Exclusion Criteria: 

  • Participants unable to provide informed medical consent.
  • Participants admitted to Intensive Care Units (ICU). Enrollment is possible after transferring out of the ICU.  
  • Actively being treated for DKA (diabetes ketoacidosis) or HHS (hyperosmolar hyperglycemic state)
  • Patients with a diagnosis of liver cirrhosis.
  • Patients with a diagnosis of ESRD or Acute Renal Failure on hemodialysis or peritoneal dialysis.
  • Patients with planned MRI or surgical procedure. Enrollment is possible after MRI or surgery.
  • Participants with allergy to medical grade adhesive or medical tape.
  • Participants who are pregnant, wanting to become pregnant, or nursing during study period.
  • Participants using Medtronic and Dexcom sensors and taking acetaminophen more than 4g per day or more than 1gm every 6 hours.
  • Participants using Dexcom sensors and taking hydroxyurea.
  • Participants using Libre sensors and taking over 500 mg of ascorbic acid.
  • Patients using Eversense sensors and taking tetracycline type of antibiotics. 
  • Participants actively enrolled in other studies addressing their CGM use unless express permission is obtained from prior study research team principal investigator or co-principal investigator.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 4/10/2025. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Adrian Dumitrascu, M.D.

Contact us for the latest status

Contact information:

Adrian Dumitrascu M.D.

(904) 956-0081

Dumitrascu.Adrian@mayo.edu

More information

Publications

Publications are currently not available